

The Hippo Pathway: Signaling, Cancer, and Beyond

May 8-11, 2019 | San Diego, CA

AACR American Association for Cancer Research

Poster Session A

Thursday, May 9

12:30-2:30 pm

A01 YAP1 drives ependymoma-like tumour formation in the brain. Noreen Eder, The Francis Crick Institute, London, United Kingdom.

A02 YAP1 opposes differentiation in mesenchymal tumors. T.S. Karin Eisinger-Mathason, University of Pennsylvania, Philadelphia, PA.

A03 Generation of primary sarcoma mouse models through CRISPR/Cas9 mediated activation of Yap1. Jianguo Huang, Duke University, Durham, NC.

A04 Genetic and pharmacologic inhibition of HES1 reduces YAP1 expression, impairing rhabdomyosarcoma cell growth. Alexander Kovach, Duke University, Durham, NC.

A05 RAS signaling promotes ERMS cell viability via sustaining TAZ expression and protein stability. Liz (Yi-Tzu) Lin, Duke University Medical Center, Durham, NC.

A06, PR03 YAP/TAZ requirement in mesenchyme-originated intestinal hamartomatous polyposis. Junhao Mao, University of Massachusetts Medical School, Worcester, MA.

A07 Role of YAP/TEAD and YAP/Smad signaling pathways in osteosarcoma tumour growth and lung metastasis dissemination. Sarah Morice, INSERM, Nantes, France.

A08 Loss of non-canonical Hippo signaling in fusion-positive alveolar rhabdomyosarcoma increases invasiveness and a dedifferentiated phenotype associated with metastasis. Kristianne Oristian, Duke University Medical Center, Durham, NC.

A09 Targeting Hippo-dependent and Hippo-independent regulation of the YAP1 oncoprotein in childhood rhabdomyosarcoma. Katherine Slemmons, Children's Hospital Los Angeles, Los Angeles, CA.

A10 Taz regulates aging of hematopoietic stem cells. Anna Mura-Meszaros, Leibniz Institute on Aging, Jena, Germany.

A11 Reawakening the regenerative potential of mammalian Müller glial cells to restore sight. Ross Poche, Baylor College of Medicine, Houston, TX.

A12 YAP and cancer stem cells in basal-like breast cancer. Hazel Quinn, MDC Berlin, Berlin, Germany.

A13 Yap activity in bile ducts, but not in hepatocytes, is required for normal liver regeneration. Elisabeth Verboven, VIB - KULeuven, Leuven, Belgium.

A14, PR10 Hippo Regulates Intestinal Regeneration By Inducing Revival Stem Cells. Jeff Wrana, Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada.

A15 A balance of yki/sd activator and e2f1/sd repressor complexes controls cell survival and affects organ size. Peng Zhang, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

A16 The α-Arrestin ARRDC3 functions as a metastasis suppressor by regulating GPCR activation of the Hippo pathway. Aleena Arakaki, UC San Diego, San Diego, CA.

A17 The Tyrosine Phosphatase SHP2 regulates YAPY357 Phosphorylation, Sub-cellular Localization, and Transcriptional Co-Activity in Cholangiocarcinoma. EeeLN Buckarma, Mayo Clinic, Rochester, MN.

A18 Location, location, location: Avenues to regulating Hippo. Philamer C Calses, Genentech Inc., South San Francisco, CA.

A19 Regulation of glioblastoma tumor growth and stem cell properties through Gα12 and tissue factor, upstream and downstream players in YAP signaling. Olga Chaim, UCSD, La Jolla, California.

A20 Gαq controls the Hippo Pathway through MOB1 tyrosine phosphorylation by FAK. Xiaodong Feng, Moores Cancer Center, University of California, San Diego, La Jolla, California.

A21, PR02 Spatial resets modulate YAP-dependent transcription. Matt Franklin, Stanford University, Stanford, CA.

A22, PR04 Integrin-mediated mechano-transduction controls HER2 oncogenic signaling and activation of YAP in breast cancer. Filippo Giancotti, UT MD Anderson Cancer Center, Houston, TX.

A23 Verteporfin as a new treatment paradigm for platinum-resistant ovarian cancer cells. Radhika Gogoi, Geisinger Clinic, Danville, PA.

A24 Functional annotation of the Hippo somatic mutations in human cancer. Han Han, Department of Development and Cell Biology, University of California, Irvine, Irvine, CA.

A25, PR06 Mechanistic Insights for TEAD/YAP Activation. Jeffrey Holden, Genentech, South San Francisco, CA.

A26 Classification of glioblastoma tumorsphere depending on the regulatory mechanisms of the Hippo pathway. Seok-Gu Kang, Departments of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Seoul, Korea.

A27 Increasing proximity triggers Mst2 autophosphorylation. Jennifer Kavran, Johns Hopkins School of Public Health, Baltimore, MD.

A28 DEAD-box RNA helicase DP103 enhances YAP sumoylation for YAP-TEAD dependence and statin sensitivity in triple negative breast cancer. Xianning Lai, Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.

A29 Genome-wide CRISPR/Cas9 screens for the identification of novel YAP1/TAZ modulators. Martin Lange, Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany.

A30 Super-enhancer-associated Long Noncoding RNA UCA1 Interacts Directly with AMOT to Inhibit Hippo Signaling Pathway in Epithelial Ovarian Cancer. Xianzhi Lin, Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.

A31 Transcriptional addiction to YAP1 -a major driving force of oral cancer carcinogenesis and evolution ? Muneyuki Masuda, Department of Head and Neck Surgery, National Kyushu Cancer Cente, Fukuoka, Fukuoka, Japan.

A32 The small GTPase Rac1 controls the stability of Yes-Associated Protein (YAP) independently of the LATS1/2 kinases. Chitra Palanivel, University of Nebraska Medical Center, Omaha, NE.

A33, PR01 Regulation of TEAD by p38 MAPK-induced cytoplasmic translocation. Hyun Woo Park, Yonsei University, Seoul, South Korea.

A34 Identification of a MAP kinase that regulates YAP abundance. Sanghyun Park, KAIST, Daejeon, Republic of Korea.

A35 Title: Regulation of the Hippo signaling pathway through ubiquitin-mediated degradation of TEAD transcription factors. Trang Pham, Genentech, South San Francisco, CA.

A36 Paracrine orchestration of intestinal tumorigenesis at the mesenchymal-epithelial interface. Manolis Roulis, Yale School of Medicine, New Haven, CT.

A37 Implication of targeting YAP1 in KRAS-mutant lung cancer cells. Iwao Shimomura, National Cancer Center Research Institute, Tokyo, Japan.

A38 A 4-gene YAP-related pathway expression signature informs about dependence of tumors on Hippo pathway signaling. Dirk Wienke, Merck KGaA, Biopharma, R&D, Darmstadt, Germany.

A39, PR09 The Hippo pathway integrates PI3K-Akt signals with mechanical cues to control tissue growth. Barry Thompson, Francis Crick Institute, London, England, United Kingdom.

A40 Hippo signaling in cancer development. Wenqi Wang, University of California, Irvine, Irvine, CA.

A41 Inhibition of aberrant YAP and TAZ activity to prevent metastasis formation and growth. Janine Warren, Albany Medical College, Albany, NY.

A43 Identification of novel YAP/TAZ regulators in metastatic cancer. Yuxuan Xiao, Albany Medical College, Albany, NY.

A44 PR55α regulatory subunit of PP2A inhibits the MOB1/LATS cascade and activates YAP in pancreatic cancer cells. Ying Yan, University of Nebraska Medical Center, Omaha, NE.